Previous 10 | Next 10 |
IGM Biosciences (NASDAQ:IGMS +120.3%) stock soared following its Q4 results and announcing a collaboration with Sanofi (SNY) for oncology and autoimmune disorder programs potentially worth over $6B. The company's Q4 research and development expenses rose to $39.17M, compared to $19....
Gainers: IGM Biosciences IGMS +37%. TRxADE HEALTH MEDS +21%. Ginkgo Bioworks DNA +14%. NexImmune NEXI +13%. BioSig Technologies (BSGM) +8%. Losers: NeoGenomics NEO -34%. Progenity PROG -25%. Aveanna Healthcare (AVAH) -21%. Kala Pharmaceuticals...
The stock market has bounced sharply from its lows last month, and the gains looked poised to continue on Tuesday morning. Even with rising interest rates, the ongoing war in Ukraine, and uncertainty about the coming earnings season, investors nevertheless appear to believe that stocks repr...
Guardforce AI (GFAI) +46% is expanding it footprint by establishing subsidiaries in Dubai and Australia. IGM Biosciences (IGMS) +32% on proposed stock offering. Hycroft Mining Holding (HYMC) +23% GameStop, AMC and Bed Bath pull off a meme stock comeback. Nielsen Holdi...
IGM Biosciences (NASDAQ:IGMS) shares have surged ~36% pre-market after the biotech firm announced an underwritten public offering of $200M shares if its common stock, and in lieu of common stock to certain investors that so choose, non-voting common stock. Terms of the offering are ...
IGM Biosciences press release (NASDAQ:IGMS): Q4 GAAP EPS of -$1.50 beats by $0.04. Cash and investments as of December 31, 2021 were $229.5M, compared to $366.3M as of December 31, 2020. Shares +38% PM. For further details see: IGM Biosciences GAAP EPS of -$1.50 beats by $0.04...
– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones – – ...
MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that the Company will host a conference call and live audio webcast today, Tue...
Gainers: Sera Prognostics (SERA) +10%. Harte-Hanks (HHS) +7%. Precigen (PGEN) +5%. Greenidge Generation Holdings (GREE) +5%. IGM Biosciences (IGMS) +5%. Losers: Connect Biopharma Holdings Limited (CNTB) -17%. Arhaus (ARHS) -5%. Fluent (FLNT) -5%. Marinus Pharmaceuticals ...
IGMS develops IgM antibodies targeting cancer. The science is neat, however, trial results published at the last two ASH conferences didn't impress investors. The company has a short cash runway of 3-4 quarters at most. For further details see: IGM Biosciences: Interesti...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 5.6% to $127.4 on volume of 368,729,821 shares Maxeon Solar Technologies Ltd. (MAXN) rose 14.2% to $0.2407 on volume of 294,399,898 shares Kazia Therapeutics Limited (KZIA) rose 85.6% to $1.24 on volume ...
2024-05-31 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 12:15:03 ET RBC Capital analyst issues UNDERPERFORM recommendation for IGMS on May 24, 2024 10:00AM ET. The previous analyst recommendation was Underperform. IGMS was trading at $10.01 at issue of the analyst recommendation. The overall analyst consensus : BUY...